

Resource Summary Report

Generated by [kravitz2](#) on Aug 11, 2026

MSCV-IRES-Thy1.1 DEST

RRID:Addgene_17442

Type: Plasmid

Proper Citation

RRID:Addgene_17442

Plasmid Information

URL: <http://www.addgene.org/17442>

Proper Citation: RRID:Addgene_17442

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:16873067](#)

Vector Backbone Description: Backbone Marker:Philippa Marrack Lab; Backbone Size:6063; Vector Backbone:MSCV-IRES-Thy1.1; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Comments: Recombination sites were added to MSCV-IRES-Thy1.1 for subcloning from pENTR vectors.

Plasmid Name: MSCV-IRES-Thy1.1 DEST

Record Creation Time: 20220422T222008+0000

Record Last Update: 20260808T081247+0000

Ratings and Alerts

No rating or validation information has been found for MSCV-IRES-Thy1.1 DEST.

No alerts have been found for MSCV-IRES-Thy1.1 DEST.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Lu G, et al. (2026) In vivo detection of immune responses via cytokine activity labeling. *Cell*.

López-Hernández L, et al. (2026) BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. *bioRxiv : the preprint server for biology*.

Sugiura A, et al. (2026) Tissue and CD4 T cell subset dependence on the amino acid transporter SLC38A1. *Cell metabolism*, 38(4), 712.

Scharping NE, et al. (2026) Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function. *Cell*, 189(10), 2857.

Liu L, et al. (2025) Identification of anti-mouse PD-1 agonist antibodies that inhibit T cell activation. *Frontiers in immunology*, 16, 1631929.

Léger J, et al. (2025) The transcription factor NFIL3 drives innate lymphoid cell specification from lymphoid progenitors. *Immunity*, 58(11), 2685.

Lescale C, et al. (2025) CST Is Epistatic With Shieldin to Limit DNA Double-Strand Break End Resection and Promote Repair During Igh Class Switch Recombination. *European journal of immunology*, 55(4), e202451585.

Zheng Y, et al. (2025) An engineered viral protein activates STAT5 to prevent T cell suppression. *Science immunology*, 10(107), eadn9633.

Ganapathi Sankaran D, et al. (2025) Gene-regulatory programs that specify age-related differences during thymocyte development. *Cell reports*, 44(7), 115903.

Kadyrzhanova G, et al. (2025) Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors. *Frontiers in immunology*, 16, 1484303.

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOA as a potential immunotherapy. *Cell*, 188(18), 5062.

Zhou S, et al. (2024) Pathogenic mycobacterium upregulates cholesterol 25-hydroxylase to promote granuloma development via foam cell formation. *iScience*, 27(3), 109204.

Wang L, et al. (2024) T-bet deficiency and Hic1 induction override TGF- β -dependency in the formation of CD103⁺ intestine-resident memory CD8⁺ T cells. *Cell reports*, 43(6), 114258.

Finnigan JP, et al. (2024) Structural basis for self-discrimination by neoantigen-specific TCRs. *Nature communications*, 15(1), 2140.

Finnigan J, et al. (2023) Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs. *Research square*.

Guo M, et al. (2023) Molecular, metabolic and functional CD4 T cell paralysis impedes tumor control. bioRxiv : the preprint server for biology.

Guo M, et al. (2023) Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control. Cell reports, 42(9), 113047.

Bittner S, et al. (2022) Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy. Proceedings of the National Academy of Sciences of the United States of America, 119(40), e2208436119.

Hasim MS, et al. (2022) When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. Science advances, 8(15), eabj3286.

Aparicio B, et al. (2022) Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer. Frontiers in immunology, 13, 985886.